Breaking News Instant updates and real-time market news.

RHHBY

Roche

$29.46

0.11 (0.37%)

16:28
10/18/16
10/18
16:28
10/18/16
16:28

Genentech's TECENTRIQ approved by FDA

Genentech, a member of the Roche Group, announced that the U.S. Food and Drug Administration approved TECENTRIQ for the treatment of people with metastatic non-small cell lung cancer who have disease progression during or following platinum-containing chemotherapy, and have progressed on an appropriate FDA-approved targeted therapy if their tumor has EGFR or ALK gene abnormalities. This approval is based on results from the randomized Phase III OAK and Phase II POPLAR studies. The largest study, OAK, showed that TECENTRIQ helped people in the overall study population live a median of 13.8 months, 4.2 months longer than those treated with docetaxel chemotherapy. The study enrolled people regardless of their PD-L1 status and included both squamous and non-squamous disease types.

  • 19

    Oct

  • 19

    Oct

  • 31

    Oct

  • 06

    Nov

  • 10

    Nov

RHHBY Roche
$29.46

0.11 (0.37%)

09/01/16
BMOC
09/01/16
NO CHANGE
BMOC
Bristol-Myers has negative read through from Roche data, says BMO Capital
BMO Capital analyst Alex Arfaei says that the positive data on Roche's (RHHBY) TECENTRIQ for second line NSCLC is negative for Bristol-Myers' (BMY) cancer drug, Opdivo. The analyst does not think that TECENTRIQ's results will be superior to that of Opdivo, but he believes that Roche's drug appears to have "a significant" benefit in PD-L1 positive patients." He predicts that Roche's drug could take "meaningful market share, particularly outside of the U.S." The analyst keeps a Market Perform rating on Bristol-Myers.
09/07/16
09/07/16
NO CHANGE

BioLineRx partnering with Roche company in cancer therapy research
BioLineRx (BLRX) has entered into a collaboration with Genentech, a member of the Roche (RHHBY) Group, to support several Phase 1b studies investigating BioLineRx's BL-8040 in combination with Atezolizumab, Genentech's anti-PDL1 cancer immunotherapy, in multiple cancer indications. The Phase 1b studies will evaluate the clinical response, safety and tolerability of the combination of these therapies, as well as multiple pharmacodynamic parameters, in hematologic malignancies and solid tumors. Under the agreement, Genentech will sponsor and conduct several Phase 1b trials in multiple solid cancer indications. In addition, BioLineRx will sponsor and conduct a Phase 1b study in acute myeloid leukemia patients. The studies are designed to evaluate the safety and efficacy of the combination of BL-8040 and Atezolizumab. Upon completion of the studies, both parties will have the option to expand the collaboration to include a pivotal registration study. Additional details of the collaboration were not disclosed.
09/12/16
JEFF
09/12/16
NO CHANGE
Target $57
JEFF
Hold
Jefferies cuts Bristol-Myers price target, upgrades AstraZeneca
Jefferies analyst Jeffrey Holford lowered his price target for Bristol-Myers Squibb (BMY) to $57 from $69 saying the stock is positioned for a "rough mid term ride." The analyst sees a "difficult catalyst" set for Bristol shares with "numerous" upcoming competitor read-outs in non-small cell lung cancer. The market could see worse than expected data from Bristol's CM-026 and CM-568 studies as well as better than expected data from AstraZeneca's (AZN) MYSTIC study and Roche's (RHHBY) Chemo-IO studies in the first half of 2017, Holford tells investors in a research note. He keeps a Hold rating on Bristol and upgraded this morning AstraZeneca to Buy from Hold. Holford prefers Astra for its immunology exposure.
09/27/16
PIPR
09/27/16
NO CHANGE
Target $62
PIPR
Neutral
Bristol-Myers price target lowered to $62 from $65 at Piper Jaffray
Piper Jaffray analyst Richard Purkiss lowered his price target for Bristol-Myers Squibb (BMY) to $62 saying he sees the company ceding Opdivo's early-mover advantage in lung cancer to competitors. The analyst expects to see details from Roche's (RHHBY) positive OAK trial of Tecentriq vs. docetaxel in non-small cell lung cancer at the upcoming ESMO meeting. Purkiss also expects to see details from Merck's (MRK) positive KEYNOTE-024 trial of Keytruda. The analyst lowered his post-2016 Opdivo forecasts and reiterates a Neutral rating on Bristol shares.

TODAY'S FREE FLY STORIES

GNCA

Genocea

$5.33

0.04 (0.76%)

20:43
09/25/17
09/25
20:43
09/25/17
20:43
Downgrade
Genocea rating change at Stifel »

Genocea downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 26

    Sep

CQH

Cheniere Energy Partners LP

$24.66

0.27 (1.11%)

20:27
09/25/17
09/25
20:27
09/25/17
20:27
Initiation
Cheniere Energy Partners LP initiated at BMO Capital »

Cheniere Energy Partners…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DAL

Delta Air Lines

$48.32

-0.15 (-0.31%)

20:25
09/25/17
09/25
20:25
09/25/17
20:25
Initiation
Delta Air Lines initiated at Macquarie »

Delta Air Lines initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HA

Hawaiian Holdings

$37.45

-0.25 (-0.66%)

20:25
09/25/17
09/25
20:25
09/25/17
20:25
Initiation
Hawaiian Holdings initiated at Macquarie »

Hawaiian Holdings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Sep

ALK

Alaska Air

$74.79

0.04 (0.05%)

20:25
09/25/17
09/25
20:25
09/25/17
20:25
Initiation
Alaska Air initiated at Macquarie »

Alaska Air initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LUV

Southwest

$55.12

0.19 (0.35%)

20:25
09/25/17
09/25
20:25
09/25/17
20:25
Initiation
Southwest initiated at Macquarie »

Southwest initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DRI

Darden

$83.14

0.26 (0.31%)

, FDS

FactSet

$170.81

2.2 (1.30%)

20:25
09/25/17
09/25
20:25
09/25/17
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

DRI

Darden

$83.14

0.26 (0.31%)

FDS

FactSet

$170.81

2.2 (1.30%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 26

    Sep

SAVE

Spirit Airlines

$34.15

0.44 (1.31%)

20:22
09/25/17
09/25
20:22
09/25/17
20:22
Initiation
Spirit Airlines initiated at Macquarie »

Spirit Airlines initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

JBLU

JetBlue

$18.87

0.25 (1.34%)

20:22
09/25/17
09/25
20:22
09/25/17
20:22
Initiation
JetBlue initiated at Macquarie »

JetBlue initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALGT

Allegiant Travel

$133.95

3.85 (2.96%)

20:22
09/25/17
09/25
20:22
09/25/17
20:22
Initiation
Allegiant Travel initiated at Macquarie »

Allegiant Travel…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

AAL

American Airlines

$47.70

0.64 (1.36%)

20:22
09/25/17
09/25
20:22
09/25/17
20:22
Initiation
American Airlines initiated at Macquarie »

American Airlines…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Oct

UAL

United Continental

$59.44

0.64 (1.09%)

20:21
09/25/17
09/25
20:21
09/25/17
20:21
Initiation
United Continental initiated at Macquarie »

United Continental…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Oct

LUV

Southwest

$55.12

0.19 (0.35%)

20:10
09/25/17
09/25
20:10
09/25/17
20:10
Initiation
Southwest initiated at Macquarie »

Southwest initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMPH

Amphastar

$16.27

0.17 (1.06%)

, AVDL

Avadel Pharmaceuticals

$9.45

-0.16 (-1.66%)

18:59
09/25/17
09/25
18:59
09/25/17
18:59
Hot Stocks
Amphastar announces FDA approval of Neostigmine Methylsulfate Injection, USP »

Amphastar (AMPH)…

AMPH

Amphastar

$16.27

0.17 (1.06%)

AVDL

Avadel Pharmaceuticals

$9.45

-0.16 (-1.66%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 26

    Sep

  • 04

    Oct

  • 05

    Oct

ACN

Accenture

$138.16

0.26 (0.19%)

18:58
09/25/17
09/25
18:58
09/25/17
18:58
Hot Stocks
Accenture chief marketing & communications officer Taylor to retire Aug 31, 2018 »

Accenture announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Sep

  • 02

    Oct

  • 22

    Oct

SPR

Spirit AeroSystems

$78.07

-0.38 (-0.48%)

, BA

Boeing

$254.32

-2.13 (-0.83%)

18:31
09/25/17
09/25
18:31
09/25/17
18:31
Hot Stocks
Spirit AeroSystems finalizes agreement with Boeing »

Spirit AeroSystems (SPR)…

SPR

Spirit AeroSystems

$78.07

-0.38 (-0.48%)

BA

Boeing

$254.32

-2.13 (-0.83%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 27

    Sep

MOH

Molina Healthcare

$64.54

-0.78 (-1.19%)

, UNH

UnitedHealth

$191.75

-1.28 (-0.66%)

18:17
09/25/17
09/25
18:17
09/25/17
18:17
Hot Stocks
Senator Collins opposes Graham-Cassidy ACA repeal bill »

U.S. Senator Susan…

MOH

Molina Healthcare

$64.54

-0.78 (-1.19%)

UNH

UnitedHealth

$191.75

-1.28 (-0.66%)

CNC

Centene

$90.33

-1.89 (-2.05%)

WCG

WellCare

$164.15

-3.01 (-1.80%)

CI

Cigna

$181.44

-1.3 (-0.71%)

ANTM

Anthem

$181.50

-1.36 (-0.74%)

HNT

Health Net

HUM

Humana

$237.21

-1.88 (-0.79%)

AET

Aetna

$151.98

-1.59 (-1.04%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 26

    Sep

  • 27

    Sep

  • 24

    Oct

  • 08

    Nov

18:15
09/25/17
09/25
18:15
09/25/17
18:15
General news
Breaking General news story  »

Minneapolis Federal…

CATM

Cardtronics

$26.10

-3.17 (-10.83%)

18:13
09/25/17
09/25
18:13
09/25/17
18:13
Downgrade
Cardtronics rating change at William Blair »

Cardtronics downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IVTY

Invuity

$7.80

-0.5 (-6.02%)

18:10
09/25/17
09/25
18:10
09/25/17
18:10
Recommendations
Invuity analyst commentary at Piper Jaffray »

Invuity's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 16

    Nov

MOH

Molina Healthcare

$64.54

-0.78 (-1.19%)

, UNH

UnitedHealth

$191.75

-1.28 (-0.66%)

18:05
09/25/17
09/25
18:05
09/25/17
18:05
Hot Stocks
CBO: Graham-Cassidy ACA repeal bill to reduce number of insured by 'millions' »

The Congressional Budget…

MOH

Molina Healthcare

$64.54

-0.78 (-1.19%)

UNH

UnitedHealth

$191.75

-1.28 (-0.66%)

CNC

Centene

$90.33

-1.89 (-2.05%)

WCG

WellCare

$164.15

-3.01 (-1.80%)

CI

Cigna

$181.44

-1.3 (-0.71%)

ANTM

Anthem

$181.50

-1.36 (-0.74%)

HNT

Health Net

HUM

Humana

$237.21

-1.88 (-0.79%)

AET

Aetna

$151.98

-1.59 (-1.04%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 26

    Sep

  • 27

    Sep

  • 24

    Oct

  • 08

    Nov

GPC

Genuine Parts

$93.22

5.24 (5.96%)

18:04
09/25/17
09/25
18:04
09/25/17
18:04
Recommendations
Genuine Parts analyst commentary at RBC Capital »

Genuine Parts acquisition…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 19

    Oct

  • 30

    Oct

AA

Alcoa

$45.29

-0.09 (-0.20%)

, FCX

Freeport McMoRan

$13.89

-0.17 (-1.21%)

17:55
09/25/17
09/25
17:55
09/25/17
17:55
Recommendations
Alcoa, Freeport McMoRan, Teck Resources, Newmont Mining, Warrior Met Coal, Cleveland-Cliffs analyst commentary at Morgan Stanley »

Morgan Stanley raising…

AA

Alcoa

$45.29

-0.09 (-0.20%)

FCX

Freeport McMoRan

$13.89

-0.17 (-1.21%)

TECK

Teck Resources

$21.24

-0.72 (-3.28%)

NEM

Newmont Mining

$38.63

0.74 (1.95%)

HCC

Warrior Met Coal

$24.11

0.76 (3.25%)

CLF

Cleveland-Cliffs

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 02

    Oct

  • 20

    Oct

  • 26

    Oct

17:55
09/25/17
09/25
17:55
09/25/17
17:55
Conference/Events
Federal Reserve Bank of Minneapolis President participates in a discussion »

Minneapolis Federal…

FTK

Flotek

$5.40

0.04 (0.75%)

17:49
09/25/17
09/25
17:49
09/25/17
17:49
Earnings
Flotek cuts Q3 revenue view by $5M, consensus $90.9M »

Flotek announced impacts…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 14

    Nov

  • 16

    May

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.